Novartis faces securities fraud probe after drug trial failure causes stock to drop 14%.

Novartis announced that its Phase III trial for del-desiran in myotonic dystrophy type 1 patients failed to show significant improvement, leading to a nearly 14% drop in its American Depositary Share price. Following this, Pomerantz LLP launched an investigation into whether Novartis and some of its executives engaged in securities fraud or other illegal business practices. Investors affected by the stock decline are encouraged to contact the law firm for potential class action participation. This probe could lead to legal challenges and impact Novartis's reputation and stock performance further.

Novartis shares are trading at USD 141.66 on Pluang as of Oct 08, 2026 21:13 WIB, down 1.13% for the day, closer to its 52-week low of USD 121.80 than its high of USD 168.62. The stock's dividend yield stands at 3.31%, while the platform sees a strong sell sentiment with 97% of orders being sell. This trading context highlights investor caution following the recent negative news about Novartis's trial results.